KR101464337B1 - Composition for anti-obesity comprising extract of Diospyros lotus as effective component - Google Patents
Composition for anti-obesity comprising extract of Diospyros lotus as effective component Download PDFInfo
- Publication number
- KR101464337B1 KR101464337B1 KR1020130061417A KR20130061417A KR101464337B1 KR 101464337 B1 KR101464337 B1 KR 101464337B1 KR 1020130061417 A KR1020130061417 A KR 1020130061417A KR 20130061417 A KR20130061417 A KR 20130061417A KR 101464337 B1 KR101464337 B1 KR 101464337B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- obesity
- leaf extract
- leaf
- group
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 79
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 244000022372 Diospyros lotus Species 0.000 title abstract description 17
- 235000003333 Diospyros lotus Nutrition 0.000 title abstract description 16
- 230000003579 anti-obesity Effects 0.000 title abstract description 7
- 208000008589 Obesity Diseases 0.000 claims abstract description 24
- 235000020824 obesity Nutrition 0.000 claims abstract description 24
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 235000013305 food Nutrition 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 6
- 238000009835 boiling Methods 0.000 claims description 5
- 230000006872 improvement Effects 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 3
- 240000002853 Nelumbo nucifera Species 0.000 claims 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims 1
- 240000000278 Syzygium polyanthum Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 210000004369 blood Anatomy 0.000 abstract description 12
- 239000008280 blood Substances 0.000 abstract description 12
- 150000002632 lipids Chemical class 0.000 abstract description 7
- 230000037237 body shape Effects 0.000 abstract description 6
- 230000037396 body weight Effects 0.000 abstract description 6
- 230000036541 health Effects 0.000 abstract description 6
- 206010067125 Liver injury Diseases 0.000 abstract description 4
- 231100000234 hepatic damage Toxicity 0.000 abstract description 4
- 230000008818 liver damage Effects 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 241000196324 Embryophyta Species 0.000 abstract description 3
- 235000013376 functional food Nutrition 0.000 abstract description 2
- 230000005764 inhibitory process Effects 0.000 abstract 1
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 34
- 235000009200 high fat diet Nutrition 0.000 description 21
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 15
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 15
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 15
- 235000005875 quercetin Nutrition 0.000 description 15
- 229960001285 quercetin Drugs 0.000 description 15
- 239000003814 drug Substances 0.000 description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 13
- 210000005228 liver tissue Anatomy 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 10
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 10
- 108010023302 HDL Cholesterol Proteins 0.000 description 9
- 101000856500 Bacillus subtilis subsp. natto Glutathione hydrolase proenzyme Proteins 0.000 description 8
- 241000283707 Capra Species 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 5
- 230000004584 weight gain Effects 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000021050 feed intake Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 241000272814 Anser sp. Species 0.000 description 3
- 240000001980 Cucurbita pepo Species 0.000 description 3
- 235000009852 Cucurbita pepo Nutrition 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- -1 maltose and sucrose Chemical compound 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000002474 noradrenergic effect Effects 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- GUAFOGOEJLSQBT-UHFFFAOYSA-N scoparone Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(OC)=C2 GUAFOGOEJLSQBT-UHFFFAOYSA-N 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 1
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- OKXFBEYCJRMINR-UHFFFAOYSA-N 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one;hydrate Chemical compound O.C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 OKXFBEYCJRMINR-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 240000002245 Acer pensylvanicum Species 0.000 description 1
- 235000006760 Acer pensylvanicum Nutrition 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000269837 Artemisia dubia Species 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 101100168093 Caenorhabditis elegans cogc-2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- GSFDOOHGKOHDEL-UHFFFAOYSA-N Dalpanitin Natural products COc1cc(ccc1O)C2=COc3c(C4OC(CO)C(O)C(O)C4O)c(O)cc(O)c3C2=O GSFDOOHGKOHDEL-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 description 1
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 1
- 238000013218 HFD mouse model Methods 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 239000004158 L-cystine Substances 0.000 description 1
- 235000019393 L-cystine Nutrition 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101100221487 Mus musculus Cog2 gene Proteins 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- QWJSAWXRUVVRLH-UHFFFAOYSA-M choline bitartrate Chemical compound C[N+](C)(C)CCO.OC(=O)C(O)C(O)C([O-])=O QWJSAWXRUVVRLH-UHFFFAOYSA-M 0.000 description 1
- 229960004874 choline bitartrate Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 229960004597 dexfenfluramine Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229960001582 fenfluramine Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- SVHDRHWULLNMQC-UHFFFAOYSA-N scoparone Natural products C1=CC(=O)OC2=C1C=C(C(=O)C)C(C(C)=O)=C2 SVHDRHWULLNMQC-UHFFFAOYSA-N 0.000 description 1
- 208000037812 secondary pulmonary hypertension Diseases 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000002295 serotoninergic effect Effects 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/40—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by drying or kilning; Subsequent reconstitution
- A23L3/44—Freeze-drying
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 고욤나무 추출물을 유효성분으로 함유하는 항비만용 조성물에 관한 것으로, 더욱 상세하게는 고욤나무 (Diospyros lotus L.) 잎 추출물을 유효성분으로 함유하는 비만 예방 또는 개선용 식품 조성물 및 약학 조성물과 고욤나무 잎 추출물의 치료적 유효량을 인간을 제외한 포유류에게 투여하여 비만을 개선하는 방법에 관한 것이다.The present invention relates to a composition for anti-obesity containing a date-plum extract as an active ingredient, and more particularly, to date-plum (Diospyros lotus L.) leaf extract as an active ingredient, and a method for improving obesity by administering to a mammal other than a human a therapeutically effective amount of a gomoe leaf extract.
최근 경제발전에 따른 생활수준의 향상으로 인하여 위생 환경이 개선되고 식생활의 향상으로 섭취 열량 또한 급속한 증가가 이루어지고 있다. 그러나 음식으로 섭취하는 열량 증가에 비해 육체 노동 및 운동 등으로 소비하는 열량이 적어 비만인구가 증가하고 있다. 비만은 다양한 요인들이 관여하는 복합적 증후군으로 과도한 에너지 섭취 후 대사활동에 사용되고 남은 에너지원들이 지방조직에 체지방으로 축척되어 발생한다. 비만은 심리적이나 사회적으로 자신의 자존감을 낮추며, 관상동맥질환, 고혈압, 뇌졸중, 당뇨병, 심혈관계 질환과 같은 만성대사질환을 야기하기 때문에 문제가 되고 있다. 이러한 만성대사질환을 예방할 수 있는 생리활성물질과 건강기능성 식품에 대한 관심이 점차 높아지고 있으며, 특히 과일과 채소에는 플라보노이드와 폴리페놀 같은 생리활성물질이 다량 포함되어 있어, 인체의 생리기능을 증진시키는 중요한 식품으로 관심을 받고 있다. In recent years, due to the improvement of living standards due to economic development, the hygiene environment has been improved and the caloric intake has been rapidly increasing due to the improvement of the eating habits. However, compared with the increase in calories consumed by food, the number of obese people is increasing because of the low calories consumed by physical labor and exercise. Obesity is a complex syndrome in which various factors are involved. It is used for metabolic activities after excessive energy consumption, and the remaining energy sources are accumulated in body fat in fat tissue. Obesity is psychologically and socially problematic because it lowers self-esteem and causes chronic metabolic diseases such as coronary artery disease, hypertension, stroke, diabetes and cardiovascular disease. There is a growing interest in physiologically active substances and health functional foods that can prevent such chronic metabolic diseases. In particular, fruits and vegetables contain a large amount of physiologically active substances such as flavonoids and polyphenols, I am interested in food.
만성 대사성 질환의 주원인인 비만을 해결하기 위하여 비만 치료제의 개발과 연구는 계속되고 있지만 항비만 약물들은 부작용이 심해 완전한 치료제는 없는 실정이다. 현재 비만을 치료하는 치료제로는 크게 중추 신경계에 작용하여 식욕에 영향을 주는 약제와 위장관에 작용하여 흡수를 저해하는 약물로 나누어 볼 수 있다. 중추 신경계에 작용하는 약물로는 각각의 기전에 따라 세로토닌 (5-HT) 신경계를 저해하는 펜플루라민, 덱스펜플루라민 등의 약물, 노르아드레날린 신경계를 통한 에페드린 및 카페인 등의 약물 및 최근에는 세로토닌 및 노르아드레날린 신경계에 동시 작용하여 비만을 저해하는 시부트라민 등의 약물들이 시판되고 있다. 이외에도, 위/장관에 작용하여 비만을 저해하는 약물로 장관 리파제를 저해하여 지방의 흡수를 줄여주는 비만 치료제로 허가된 오를리스타트 등이 대표적인 약물이 사용되고 있다. 그러나 기존에 사용되어온 약물 중 펜플루라민 등의 약물은 부작용으로 원발성 폐고혈압이나 심장 판막병변을 일으켜 최근에 사용이 금지되었으며, 다른 약물들도 혈압감소나 유산 산혈증 등의 문제점이 발생하여 심부전, 신질환 등의 환자에는 사용하지 못하는 문제점이 있다. 따라서 최근에는 비만 치료를 위해 안전성이 높은 천연물질 유래의 항비만 및 체형 개선 소재를 찾아내고 이들의 메커니즘을 밝히는 연구들이 활발하게 진행되고 있다.Although the development and research of obesity treatment is continuing to solve obesity which is the main cause of chronic metabolic diseases, anti - obesity drugs have serious side effects and there is no complete treatment. Current treatments for treating obesity include drugs that act on the central nervous system, affect appetite, and drugs that act on the gastrointestinal tract to inhibit absorption. Drugs such as fenfluramine and dexfenfluramine, which inhibit the serotonin (5-HT) nervous system, drugs such as ephedrine and caffeine through the noradrenergic nervous system, and drugs such as serotonin and noradrenergic nervous system And sibutramine, which inhibits obesity, are commercially available. In addition, a drug that acts on the stomach / intestines to inhibit obesity is a representative drug such as Orlistat, which is approved as a treatment for obesity that inhibits intestinal lipase and reduces fat absorption. However, medications such as pfenfluramine, which have been used in the past, cause secondary pulmonary hypertension or heart valve lesions due to side effects. Recently, other medications have also been reported to cause problems such as decreased blood pressure and acidosis. There is a problem that patients can not use. Therefore, in recent years, researches have been actively carried out to find anti-obesity and body shape improving materials derived from natural materials with high safety for treating obesity and to clarify their mechanisms.
고욤나무 (Diospyros lotus L.)는 우리나라와 중국을 비롯한 아시아에서 자연적으로 자생하는 낙엽성 식물로 전통의학에서는 성숙한 고욤 과실을 진정, 진통, 수렴 및 변비 치료에 사용해왔다. 고욤은 지방산, 당, 플라보노이드 및 비휘발성 물질 등의 생화학적 성분을 함유하는 것으로 보고되었고, 최근에는 혈액의 항응고, 뇌세포 보호 작용, 항산화 및 항암 효과에 대한 보고가 있다. 이러한 고욤의 효과에 대한 연구는 주로 고욤 과실과 씨를 대상으로 하고 있다 (Moghaddam et al ., 2012, Acta Pol Pharm, 69(4):687-92). 그러나 고욤나무 잎 추출물을 이용한 항비만 및 체형 개선에 대한 연구는 전무한 실정이다.Goomae ( Diospyros lotus L.) is a naturally occurring deciduous plant native to Korea and China including Asia. In traditional medicine, mature Gomilla fruit has been used for sedation, analgesia, convergence and constipation treatment. Goyom has been reported to contain biochemical components such as fatty acids, sugars, flavonoids and nonvolatile substances. Recently, there have been reports of anticoagulation, brain cell protection, antioxidant and anticancer effects of blood. Studies on the effectiveness of Goyom are mainly directed to Goyom fruits and seeds (Moghaddam et al . , 2012, Acta Pol Pharm , 69 (4): 687-92). However, there has been no study on the improvement of anti - obesity and body shape using the extract of Goyomumu leaf.
한편, 한국공개특허 제2008-0090169호에는 '쑥 또는 율피 추출물 또는 이로부터 분리된 스코파론을 함유하는 체중조절용 조성물'이 개시되어 있다. 그러나 본 발명에서와 같이 고욤나무 추출물을 유효성분으로 함유하는 항비만용 조성물에 대해서는 개시된 바가 없다.Korean Patent Laid-Open Publication No. 2008-0090169 discloses a composition for controlling weight, which contains an extract of Mugwort or Julia or a scoparone isolated therefrom. However, as described in the present invention, no anti-obesity composition containing the extract of Gomam tree as an active ingredient has been disclosed.
본 발명은 상기와 같은 요구에 의해 도출된 것으로서, 고욤나무 (Diospyros lotus L.) 잎 추출물을 고지방 사료와 함께 투여한 마우스에서 고지방 사료만 투여한 마우스에 비해 우수한 체중 증가 억제, 간 손상 억제 및 혈중 지질 함량 증가 억제 효과를 나타내는 것을 통해 고욤나무 잎 추출물의 항비만 효과를 확인함으로써, 본 발명을 완성하였다.The present invention is derived by the request as described above, the date-plum (Diospyros lotus L.) leaf extract a high fat diet increased superior compared to high-fat diet mice administered only in the mice administered with the suppressing body weight, liver damage and inhibit blood The present invention has been accomplished by confirming the anti-obesity effect of the extract of Gomam tree leaf by showing the effect of inhibiting the increase of lipid content.
상기 과제를 해결하기 위해, 본 발명은 고욤나무 (Diospyros lotus L.) 추출물을 유효성분으로 함유하는 비만 예방 또는 개선용 식품 조성물을 제공한다.In order to solve the above problems, the present invention goyom tree (Diospyros lotus L.) extract as an active ingredient.
또한, 본 발명은 고욤나무 추출물을 유효성분으로 함유하는 비만 예방 또는 치료용 약학 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for preventing or treating obesity, comprising the extract of Guillaume extract as an active ingredient.
또한, 본 발명은 고욤나무 잎 추출물의 치료적 유효량을 인간을 제외한 포유류에게 투여하여 비만을 개선하는 방법을 제공한다.In addition, the present invention provides a method for improving obesity by administering a therapeutically effective amount of Gomexiaceae leaf extract to mammals other than humans.
본 발명에 따르면, 고욤나무 (Diospyros lotus L.) 잎 추출물은 체중 증가 억제, 간 손상 억제 및 혈중 지질 함량 증가 억제 효과가 우수하며, 식물로부터 추출된 물질이므로 부작용을 일으키지 않고, 비만 및 체형 개선용 조성물 또는 건강 식품으로 유용하게 사용될 수 있다.According to the invention, the date-plum (Diospyros lotus L.) leaf extract has excellent effect of inhibiting weight gain, suppressing liver damage and increasing blood lipid content, and being a plant-derived substance, it can be used as a composition for improving obesity and body shape or as a health food without causing side effects have.
도 1은 일반 사료 (정상군), 고지방 사료 (대조군), 고욤잎 추출물 혼합 고지방 사료 또는 쿼세틴 (Quercetin) 혼합 고지방 사료 투여에 따른 마우스 체형 변화를 측정한 사진이다.
도 2는 일반 사료 (정상군), 고지방 사료 (대조군), 고욤잎 추출물 혼합 고지방 사료 또는 쿼세틴 혼합 고지방 사료 투여에 따른 마우스 간 조직의 지방 축적 정도를 측정한 사진이다. 지방 축적 정도는 간 조직을 오일레드 (oil red)로 염색하여 측정하였다. 현미경 배율: ×100.FIG. 1 is a photograph showing changes in mouse body shape according to administration of a general diet (normal group), a high fat diet (control group), a high fat diet mixed with goat's leaf extract or a high fat diet containing quercetin.
FIG. 2 is a photograph showing the degree of fat accumulation of mouse liver tissue according to administration of a general diet (normal group), a high fat diet (control group), a high fat diet mixed with goat's leaf extract or a high fat diet containing quercetin. The degree of fat accumulation was measured by staining liver tissue with oil red. Microscope magnification: × 100.
본 발명의 목적을 달성하기 위하여, 본 발명은 고욤나무 (Diospyros lotus L.) 추출물을 유효성분으로 함유하는 비만 예방 또는 개선용 식품 조성물을 제공한다.According to an aspect of the invention there is date-plum (Diospyros lotus L.) extract as an active ingredient.
또한, 본 발명의 비만 예방 또는 개선용 식품 조성물에서, 고욤나무 추출물은 고욤나무 잎, 과실, 씨, 줄기 또는 뿌리 추출물일 수 있으며, 바람직하게는 잎 추출물일 수 있으나, 이에 제한되지 않는다.In addition, in the food composition for preventing or improving obesity of the present invention, the gomam tree extract may be a gomam tree leaf, a fruit, a seed, a stem or a root extract, preferably a leaf extract, but is not limited thereto.
본 발명의 비만 예방 또는 개선용 식품 조성물에서, 상기 고욤나무 잎 추출물은 고욤나무 잎의 물, 메탄올, 에탄올, 프로판올, 부탄올, 에틸 아세테이트 또는 이들의 혼합 용매의 추출물일 수 있고, 바람직하게는 물 추출물일 수 있으며, 더욱 바람직하게는 고욤나무 잎 열수 추출물일 수 있으며, 더 더욱 바람직하게는 채취한 고욤나무 잎을 물로 세척한 후 4~10분 동안 증기로 찌고, 실온에서 수분을 제거하고 건조기에서 35~45℃로 10~14시간 동안 건조한 후, 건조된 고욤나무 잎 180~220 g에 1800~2200 ml의 물을 넣고 4~10분 동안 끓여서 얻은 추출물을 여과 및 동결 건조하여 제조될 수 있으며, 가장 바람직하게는 채취한 고욤나무 잎을 물로 세척한 후 5분 동안 증기로 찌고, 실온에서 수분을 제거하고 건조기에서 40℃로 12시간 동안 건조한 후, 건조된 고욤나무 잎 200 g에 2000 ml의 물을 넣고 5분 동안 끓여서 얻은 추출물을 여과 및 동결 건조하여 제조될 수 있으나, 이에 제한되는 것은 아니다.In the food composition for preventing or improving obesity according to the present invention, the Gomam tree leaf extract may be an extract of water, methanol, ethanol, propanol, butanol, ethyl acetate or a mixed solvent thereof, More preferably, the collected gomam leaf is washed with water, steamed for 4 to 10 minutes, removed at room temperature, and dried in a drier at 35 [deg.] C. Dried at ~ 45 ° C for 10 ~ 14 hours, and then 1800 ~ 2200 ml of water is added to 180 ~ 220g of dried gomam leaf and boiled for 4 ~ 10 minutes. The extract can be prepared by filtration and freeze drying. Preferably, the collected gomam leaf is washed with water and steamed for 5 minutes. After removing moisture at room temperature and drying in a dryer at 40 ° C for 12 hours, dried gomam leaf 20 The extract may be prepared by adding 2000 ml of water to 0 g of water and boiling for 5 minutes, followed by filtration and freeze-drying.
상기 식품은 비만을 예방하거나 개선하기 위해 섭취할 수 있는 것이면 특별히 제한되지 않는다.The food is not particularly limited as long as it can be ingested to prevent or ameliorate obesity.
본 발명의 상기 추출물을 식품첨가물로 사용하는 경우, 상기 추출물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효 성분의 혼합양은 그의 사용 목적 (예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조시에 본 발명의 추출물은 원료에 대하여 15 중량부 이하, 바람직하게는 10 중량부 이하의 양으로 첨가된다. 그러나, 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다.When the extract of the present invention is used as a food additive, the extract may be directly added, used in combination with other food or food ingredients, and suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to its intended use (prevention, health or therapeutic treatment). Generally, the extract of the present invention is added in an amount of not more than 15 parts by weight, preferably not more than 10 parts by weight, based on the raw material, in the production of food or beverage. However, in the case of long-term consumption intended for health and hygiene purposes or for health control purposes, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range .
상기 식품의 종류에는 특별한 제한은 없다. 상기 물질을 첨가할 수 있는 식품의 예로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.There is no particular limitation on the kind of the food. Examples of foods to which the above substances can be added include dairy products including meats, sausages, breads, chocolates, candies, snacks, confectionery, pizza, ramen noodles, gums, ice cream, soups, drinks, tea, Alcoholic beverages, and vitamin complexes, all of which include healthy foods in a conventional sense.
본 발명의 건강 음료 조성물은 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 슈크로스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 추출물 100 ㎖당 일반적으로 약 0.01~0.04 g, 바람직하게는 약 0.02~0.03 g일 수 있으나, 이에 제한되는 것은 아니다.The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Such natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like. The ratio of the natural carbohydrate may be generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 ml of the extract of the present invention, but is not limited thereto.
상기 외에 본 발명의 추출물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 추출물은 천연 과일 주스, 과일 주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 혼합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 조성물 100 중량부당 0.01~0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the extract of the present invention may further contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and its salts, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, A carbonating agent used in a carbonated beverage, and the like. In addition, the extract of the present invention may contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
또한, 본 발명은 고욤나무 추출물을 유효성분으로 함유하는 비만 예방 또는 치료용 약학 조성물을 제공한다. 본 발명의 약학 조성물에서, 고욤나무 추출물은 상기 식품 조성물에서 기재한 바와 같다.In addition, the present invention provides a pharmaceutical composition for preventing or treating obesity, comprising the extract of Guillaume extract as an active ingredient. In the pharmaceutical composition of the present invention, Koomomoe extract is as described in the above food composition.
본 발명의 비만 예방 또는 치료용 약학 조성물은 약학 조성물 총 중량에 대하여 상기 추출물을 0.02 내지 80 중량%, 바람직하게는 0.02 내지 50 중량%로 포함할 수 있다.The pharmaceutical composition for preventing or treating obesity of the present invention may contain 0.02 to 80% by weight, preferably 0.02 to 50% by weight of the extract, based on the total weight of the pharmaceutical composition.
본 발명의 추출물을 포함하는 약학 조성물은 약학적 조성물의 제조에 통상적으로 사용하여 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다.Pharmaceutical compositions comprising the extract of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the preparation of pharmaceutical compositions.
본 발명의 추출물의 약학적 투여 형태는 이들의 약학적 허용 가능한 염의 형태로도 사용될 수 있고, 또한 단독으로 또는 타 약학적 활성 화합물과 결합뿐만 아니라 적당한 집합으로 사용될 수 있다.The pharmaceutical dosage forms of the extract of the present invention may be used in the form of their pharmaceutically acceptable salts, and may be used alone or in combination with other pharmaceutically active compounds as well as in suitable aggregates.
본 발명에 따른 추출물을 포함하는 약학 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 추출물을 포함하는 약학 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유 등을 포함한 다양한 화합물 혹은 혼합물을 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구 투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 추출물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트 (calcium carbonate), 수크로오스 (sucrose) 또는 락토오스 (lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜 (propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔 (witepsol), 마크로골, 트윈 (tween) 61, 카카오지, 라우린지, 글리세로젤라틴 등이 사용될 수 있다.The pharmaceutical composition containing the extract according to the present invention can be administered orally in the form of powders, granules, tablets, capsules, oral preparations such as suspensions, emulsions, syrups and aerosols, external preparations, suppositories and sterilized injection solutions And can be used as formulations. Examples of carriers, excipients and diluents that can be included in the pharmaceutical composition containing the extract include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium A variety of compounds or mixtures including silicates, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose, Or lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Examples of the liquid preparation for oral administration include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin and the like.
본 발명의 추출물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나, 바람직한 효과를 위해서, 본 발명의 추출물은 1일 0.0001 내지 100 mg/kg으로, 바람직하게는 0.001 내지 100 mg/kg으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다. 또한, 본 발명에 의한 조성물은 단독으로 투여되거나 다른 약제와 동등하게 또는 다른 약제를 보조하기 위해 함께 투여될 수 있다. 또한, 각 제형의 조성물에 있어서, 상기한 필수 성분인 조성물 이외의 다른 성분들은 기타 외용제의 제형 또는 사용목적 등에 따라 당업자가 적의 선정하여 배합할 수 있으며, 이 경우 다른 원료와 동시에 적용할 경우 상승 효과가 일어날 수 있다.The preferred dosage of the extract of the present invention varies depending on the condition and the weight of the patient, the degree of disease, the type of drug, the administration route and the period of time, but can be appropriately selected by those skilled in the art. However, for the desired effect, the extract of the present invention is preferably administered at 0.0001 to 100 mg / kg, preferably 0.001 to 100 mg / kg per day. The administration may be carried out once a day or divided into several times. The dose is not intended to limit the scope of the invention in any way. In addition, the composition according to the present invention may be administered alone, or may be administered together with other medicines in order to aid in the same or another medicament. In addition, in the composition of each formulation, components other than the composition, which is the above-mentioned essential ingredient, can be mixed and selected by a person skilled in the art according to the formulation or purpose of use of the other external preparation. In this case, Can happen.
본 발명의 추출물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁 내 경막 또는 뇌혈관 내 (intracerebroventricular) 주사에 의해 투여될 수 있다.The extract of the present invention can be administered to mammals such as rats, mice, livestock, humans and the like in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine or intracerebroventricular injections.
또한, 본 발명은In addition,
(a) 채취한 고욤나무 잎을 물로 세척한 후 4~10분 동안 증기로 찌고, 실온에서 수분을 제거하고 건조기에서 35~45℃로 10~14시간 동안 건조한 후, 건조된 고욤나무 잎 180~220 g에 1800~2200 ml의 물을 넣고 4~10분 동안 끓여서 얻은 추출물을 여과 및 동결 건조하여 고욤나무 잎 추출물을 제조하는 단계; 및(a) The collected gomam leaf was washed with water and steamed for 4 to 10 minutes. After removing moisture at room temperature, it was dried at 35 to 45 ° C for 10 to 14 hours in a drier, 220 g to 1800 to 2200 ml of water, boiling for 4 to 10 minutes, and filtering and lyophilizing the extract to prepare a gomam leaf extract; And
(b) 상기 제조한 고욤나무 잎 추출물의 치료적 유효량을 인간을 제외한 포유류에게 투여하여 비만을 개선하는 방법을 제공할 수 있고,(b) a method for improving obesity by administering to a mammal other than a human a therapeutically effective amount of the gomoe tree leaf extract prepared as described above,
바람직하게는Preferably,
(a) 채취한 고욤나무 잎을 물로 세척한 후 5분 동안 증기로 찌고, 실온에서 수분을 제거하고 건조기에서 40℃로 12시간 동안 건조한 후, 건조된 고욤나무 잎 200 g에 2000 ml의 물을 넣고 5분 동안 끓여서 얻은 추출물을 여과 및 동결 건조하여 고욤나무 잎 추출물을 제조하는 단계; 및(a) The collected gomam leaf was washed with water and steamed for 5 minutes. After removing moisture at room temperature, it was dried in a dryer at 40 ° C for 12 hours. Then, 2000 g of water was added to 200 g of dried gomam leaf Followed by boiling for 5 minutes, followed by filtration and lyophilization to prepare a gomam leaf extract; And
(b) 상기 제조한 고욤나무 잎 추출물의 치료적 유효량을 인간을 제외한 포유류에게 투여하여 비만을 개선하는 방법을 제공할 수 있다.(b) A method of improving obesity by administering a therapeutically effective amount of the above-prepared gomam leaf extract to mammals other than humans.
본 발명의 상기 '치료적 유효량'은 측정 가능한 생물학적 반응을 나타내기에 충분한 치료용 조성물의 양을 의미한다.Said "therapeutically effective amount" of the present invention means an amount of therapeutic composition sufficient to exhibit a measurable biological response.
본 발명에서 포유류는 인간을 포함하거나 또는 제외한 포유류일 수 있으나, 이에 제한되지 않는다.
In the present invention, the mammal may be a mammal including, but not limited to, a human.
이하, 본 발명을 실시예에 의해 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 한정되는 것은 아니다.
Hereinafter, the present invention will be described in detail by way of examples. However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.
재료 및 방법Materials and methods
1. 시약1. Reagents
GPT (glutamic-pyruvic transaminase), GOT (glutamic-oxaloacetic transaminase (GOT), ALP (alkaline phosphatase), γ-GTP (γ-glutamyl transpeptidase), 중성지방 (tryglyceride, TG), T-CHO (total cholesterol), HDL-CHO (high density lipoprotein cholesterol) 및 총 단백질 측정용 키트는 아산제약으로부터 구입하였고, 쿼세틴 (Quercetin hydrate)과 기타 시약은 시약 등급으로 Sigma-Aldrich로부터 구입하였다.
Glutamic-pyruvic transaminase (GPT), glutamic-oxaloacetic transaminase (GOT), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase, tryglyceride (TG), total cholesterol High density lipoprotein cholesterol (HDL-CHO) and total protein measurement kits were purchased from Asan Pharmaceuticals. Quercetin hydrate and other reagents were purchased from Sigma-Aldrich as reagent grade.
2. 고욤 잎 추출물 제조2. Manufacture of gourd leaf extract
실험에 사용한 고욤 (D. lotus L.)은 전라북도 진안군 부귀면 수항리 신기마을에서 2012년 6월 30일에 채취하였다. 채취한 고욤 잎은 즉시 증류수로 세척하여 5분 동안 증기로 찐 후 실온에서 선풍기로 수분을 제거하고, 최종적으로 40℃의 건조기에서 12시간 동안 건조하였다. 건조한 고욤 잎 200 g에 증류수 2,000 ㎖를 첨가해서 5분간 끓인 후, 0.45 ㎛ 필터로 여과하여 고욤 잎 추출물을 얻었다. 여과한 고욤 잎 추출물은 동결건조기 (EYELA FDU-2100, Japan)에서 건조하여 19.5 g을 회수하였고, -20℃에서 보관하면서 실험에 사용하였다.
D. lotus L. was collected on June 30, 2012 at Shingi Village, Suwang-ri, Gugong-myeon, Jinan-gun, Jeollabuk-do. The collected leaves were immediately washed with distilled water and steamed for 5 minutes. Then, the water was removed by a fan at room temperature, and finally dried in a dryer at 40 ° C for 12 hours. 2,000 ml of distilled water was added to 200 g of dry goose leaves, and the mixture was boiled for 5 minutes, and then filtered through a 0.45 mu m filter to obtain a gomule leaf extract. The filtered goat's leaf extract was dried in a freeze dryer (EYELA FDU-2100, Japan) and recovered 19.5 g.
3. 실험 동물의 사육 및 식이3. Breeding and Diet of Laboratory Animals
실험 동물은 4주령의 C57BL/6J종 수컷 마우스 (18~20 g)를 Central Lab. Animal Inc.에서 구입했으며, 1주일 동안 사육실 환경에 적응시켰다. 사육장의 온도는 18~24℃, 상대습도는 50~60%로 유지하였으며, 명암은 12시간 주기 (09:00~21:00)로 조절하였다. 마우스는 정상 사료 투여군 (정상군; ND), 고지방 사료 투여군 (대조군; HF), 고지방 사료 및 고욤잎 추출물 투여군 (DH) 및 고지방 사료 및 쿼세틴 (Quercetin) 투여군 (QH)의 총 4군으로 무작위로 나누어 8주간 사육하였다.
Experimental animals were C57BL / 6J male mice (18 ~ 20 g) at 4 weeks of age. It was purchased from Animal Inc. and adapted to the breeding environment for one week. The temperature of the kennel was maintained at 18 ~ 24 ℃ and the relative humidity was 50 ~ 60%. The darkness was adjusted to 12 hours (09: 00 ~ 21: 00). The mice were randomly divided into four groups: normal diet (normal group; ND), high fat diet (control group; HF), high fat diet and gourd leaf extract group (DH) and high fat diet and quercetin group For 8 weeks.
4. 고지방 사료 조성 및 고지방 사료 투여에 따른 마우스 체중 변화4. Changes in mouse body weight after high fat diet and high fat diet
본 발명에서 일반 사료는 AIN-76A, 고지방 사료는 AIN-76A에 40 중량%의 돈지(Lard)가 첨가된 사료를 사용했다. 사료의 조성은 표 1과 같으며, 중앙동물실험(주)으로부터 구입했다. 고지방 사료는 4℃에 냉장 보관하면서 급여하였고, 음수와 사료는 자유롭게 섭취하도록 했다. 사료 섭취량은 3일 간격으로 측정하였고, 체중은 일주일 간격으로 측정하였다. 본 연구는 전주대학교 동물실험윤리위원회의 규정에 맞추어서 진행되었다.In the present invention, AIN-76A was used as a general feed, and 40% by weight of Lard was added to AIN-76A as a high fat feed. The composition of the feed is shown in Table 1, and it was purchased from Central Animal Experiment Co., Ltd. High fat diets were fed at 4 ° C while refrigerated, and free water and feed were allowed. Feed intake was measured at 3-day intervals, and body weights were measured at weekly intervals. This study was conducted in accordance with the regulations of the Ethical Committee of Animal Experiment of Chonju University.
1) 일반 사료: AIN-76A1) General feed: AIN-76A
2) 고지방 사료: AIN-76A + 돈지(Lard)
2) High fat feed: AIN-76A + Lard
5. 혈액의 채취 및 처리5. Blood collection and disposal
혈액은 실험이 종료되는 마지막 12주에 12시간 동안 절식시키고, 마취한 후 간문맥에서 채혈하였다. 채혈한 혈액은 4℃에서 10,000 rpm으로 10분 동안 원심분리하여 혈청을 분리하였으며, 분석 전까지 -50℃에 냉동 보관하면서 사용했다.
Blood was fasted for 12 hours during the last 12 weeks after the end of the experiment, and blood was collected from the portal vein after anesthesia. The collected blood was centrifuged at 10,000 rpm for 10 minutes at 4 ° C, and the serum was separated and used at -50 ° C until freezing.
6. 생화학적 분석6. Biochemical analysis
혈청 중 중성지방, 총 콜레스테롤, HDL (High Density Lipoprotein)-콜레스테롤, ALP, 총 단백질, 알부민, γ-GTP 및 GOT-GPT의 함량은 측정용 키트 (Asan)를 사용하여 분석했으며, LDL (Low Density Lipoprotein)-콜레스테롤 함량은 Friedewald 등 (1979, ClinChem 18: 499-502)의 방법으로 다음과 같이 계산하였다.The content of triglyceride, total cholesterol, high density lipoprotein (HDL) -cholesterol, ALP, total protein, albumin, gamma-GTP and GOT-GPT in serum was analyzed using a measurement kit (Asan) Lipoprotein) - Cholesterol content was calculated by the method of Friedewald et al. (1979, ClinChem 18: 499-502) as follows.
LDLc = (TC - HDLc) - TG/5
LDLc = (TC - HDLc) - TG / 5
7. 간 조직의 지방 축적의 관찰7. Observation of fat accumulation in liver tissue
8주간 정상 사료 또는 고지방 사료를 투여한 마우스와 고욤 잎 추출물 또는 쿼세틴을 함께 투여한 마우스 각각의 간 조직에 축적된 지방의 변화를 확인하기 위한 실험을 수행하였다. 사료 투여 종료 후 간 조직을 적출하여 급속으로 냉동 (-40℃)시켰고, 5 μm로 박절하여 오일레드 (oil red)로 염색한 후 광학현미경 (Mocam 2000)으로 관찰하였다.
Experiments were conducted to determine the changes in the fat accumulation in the liver tissues of each of the mice administered with normal or high fat diets for 8 weeks and mice treated with goosefoot leaf extract or quercetin. After the end of the feed administration, the liver tissues were harvested, rapidly frozen (-40 ° C), stained at 5 μm, stained with oil red, and observed with an optical microscope (Mocam 2000).
8. 통계처리8. Statistical processing
모든 수치는 평균±표준편차 (mean ± SD)로 표시했으며, 통계분석은 ANOVA 및 Student's t-test로 처리했다. 유의성 한계는 p<0.05 수준에서 Duncan의 다중범위검증 (Duncan's multiple range test)에 의한 사후 분석 수행으로 검증하였다.
All values were expressed as mean ± SD (mean ± SD) and statistical analysis was performed with ANOVA and Student's t-test. The significance limits were verified by Duncan's multiple range test followed by post analysis at p <0.05 level.
실시예Example 1. 고지방 사료 급여에 따른 형태학적 변화 1. Morphological changes due to feeding of high fat diets
고지방 사료를 급여한 결과, 도 1과 같이 정상군에 비해서 고지방 사료 투여 대조군은 체형의 크기가 현저하게 증가하는 것을 확인할 수 있었다. 그러나 고욤 잎 추출물을 고지방 사료와 함께 투여한 군은 정상군과 유사할 정도로 체형에 큰 변화가 없었다. 형태학적 측면에서, 그 효과는 항산화 물질로 잘 알려진 쿼세틴보다 우수한 것으로 확인되었다.
As a result of feeding the high fat diets, it was confirmed that the body type was significantly increased in the control group administered with the high fat diet as compared with the normal group as shown in Fig. However, there was no significant change in the body shape of the group treated with goat 's leaf extract with high fat diet. On the morphological side, the effect was found to be superior to quercetin, which is well known as an antioxidant.
실시예Example 2. 체중, 간 중량 및 사료 섭취량 비교 2. Comparison of body weight, liver weight and feed intake
각 군의 체중 변화 및 간 중량과 식이 섭취량의 차이는 표 2와 같다. 체중 변화를 보면, 고지방 사료만 섭취한 대조군에 비해 모든 실험군에서 체중 증가가 유의적으로 낮게 나타났다. 고욤 잎 추출물을 함께 투여한 군은 대조군에 비해 체중이 약 6.79 g 덜 증가했으며, 쿼세틴을 함께 투여한 군은 대조군에 비해 약 6.04 g 덜 증가한 것으로 나타났다. 또한, 간 중량은 대조군과 비교하여 고욤잎 추출물 투여군에서 약 0.25 g, 쿼세틴 투여군에서 약 0.2 g 정도 덜 증가한 것으로 나타났다. 이는 고지방 식이가 체중 증가와 함께 간 중량을 증가시킨다는 것을 보여주며, 고욤 잎 추출물의 섭취로 인해 체중 증가 및 간의 지방 축적이 억제되는 것을 알 수 있다.Table 2 shows the difference in body weight, liver weight and dietary intake for each group. Weight change was significantly lower in all experimental groups than in control group fed only high fat diets. Compared with the control group, the group treated with goat leaf extract showed a weight gain of about 6.79 g less, and the group administered with quercetin showed an increase of about 6.04 g less than the control group. In addition, the liver weight was found to be increased by about 0.25 g in the gomoma leaf extract group and about 0.2 g in the quercetin treated group compared to the control group. This indicates that high fat diets increase liver weight with weight gain, and weight gain and liver fat accumulation are inhibited by ingestion of gourd leaf extract.
실시예Example 3. 혈청 3. Serum GOTGOT 및 And GPTGPT 활성 activation
GOT-GPT는 간 조직의 손상을 나타내는 효소로, 간이 손상되면 간 실질세포가 파괴되어 혈액 속으로 GOT-GPT가 유리되면서 이 효소들의 활성이 높아진다. 투여한 사료에 따른 마우스의 GOT-GPT 효소 수치는 표 3에 나타내었다. 고지방 식이의 급여로 간 조직의 손상을 받은 대조군은 GOT-GPT의 수치가 가장 높게 나타났고, 고욤 잎 추출물 투여군이나 쿼세틴 투여군은 GOT-GPT 수치가 대조군에 비해 유의하게 낮게 나타났다.GOT-GPT is an enzyme that shows damage to liver tissues. When liver damage occurs, hepatic parenchymal cells are destroyed and GOT-GPT is liberated into blood, thereby increasing the activity of these enzymes. The GOT-GPT enzyme levels in the mice according to the administered diets are shown in Table 3. GOT-GPT levels were the highest in the control group, and GOT-GPT levels were significantly lower in the guacamole extract group and the quercetin group than in the control group.
실시예Example 4. γ- 4. γ- GTPGTP 및 And ALPALP 의 활성Active
간 조직의 손상을 나타내는 추가 지표로는 γ-GTP와 ALP가 있다. γ-GTP 및 ALP도 간 세포가 파괴되면 혈액 내로 유출되기 때문에 간 조직이 손상되면 높게 측정될 수 있다. γ-GTP와 ALP의 활성은 표 4에 나타내었다. γ-GTP 수치는 모든 군에서 거의 차이가 없었지만, ALP 수치의 경우에는 정상군에 비해 대조군에서 유의하게 증가한 것을 확인할 수 있었다. 반면에 고욤 잎 추출물 투여군 및 쿼세틴 투여군의 γ-GTP 수치는 대조군에 비해 유의하게 낮게 나타났으며, 쿼세틴 투여군보다 고욤 잎 추출물 투여군에서 더 낮은 것으로 나타났다. Additional indicators of liver tissue damage include γ-GTP and ALP. γ-GTP and ALP are also released into the blood when the liver cells are destroyed, so that liver tissue damage can be measured highly. The activities of γ-GTP and ALP are shown in Table 4. γ-GTP levels were not significantly different in all groups, but ALP levels were significantly increased in the control group compared to the normal group. On the other hand, the γ-GTP levels of goose leaf extract and quercetin-treated group were significantly lower than those of the control group and lower in the guacomole extract-treated group than in the quercetin-treated group.
실시예Example 5. 혈중 지질의 함량 5. Blood lipid content
혈중 지질 함량을 측정한 결과는 표 5에 나타내었다. 혈중 총 콜레스테롤 (T-CHO) 함량은 대조군이 정상군에 비해 유의하게 증가하였다. 고욤 잎 추출물 투여군 및 쿼세틴 투여군의 총 콜레스테롤 함량은 정상군에 비해 높았지만, 대조군에 비해서는 유의하게 낮은 것으로 나타났다. 혈중 중성지방 (TG) 함량 또한 대조군에서 정상군에 비해 유의하게 증가했으며, 고욤 잎 추출물 투여군 및 쿼세틴 투여군은 정상군에 비해서는 높지만, 대조군에 비해서는 유의하게 낮은 것으로 나타났다. HDL-콜레스테롤 함량은 대조군에서 정상군에 비해 유의하게 증가했으며, 고욤 잎 추출물 투여군과 쿼세틴 투여군의 HDL-콜레스테롤 증가량은 대조군에 비해 유의하게 낮았다. HDL-콜레스테롤 함량은 총 콜레스테롤 양의 증가에 따라 같이 증가한 것으로 보인다. LDL-콜레스테롤 함량 역시 HDL-콜레스테롤 함량과 비슷한 양상을 나타내었다.The results of measurement of blood lipid content are shown in Table 5. Serum total cholesterol (T-CHO) content was significantly increased in the control group compared with the normal group. The total cholesterol content of goose leaf extract and quercetin treated group was higher than that of the normal group but significantly lower than that of the control group. Serum triglyceride (TG) content was also significantly increased in the control group compared to the normal group, and that of the goat leaf extract and quercetin group was higher than that of the normal group, but significantly lower than that of the control group. HDL-cholesterol content was significantly increased in the control group as compared with the normal group, and the amount of HDL-cholesterol increase in the goat's leaf extract-treated group and quercetin-treated group was significantly lower than that of the control group. The HDL-cholesterol content seems to increase with increasing total cholesterol level. LDL-cholesterol content was also similar to HDL-cholesterol content.
1) T-CHO: 총콜레스테롤, 2) TG: 중성 지방, 3) LDL-C: LDL-콜레스테롤, 4) HDL-C: HDL-콜레스테롤. 값은 평균±표준편차를 나타낸다.
1) T-CHO: total cholesterol, 2) TG: triglyceride, 3) LDL-C: LDL-cholesterol, and 4) HDL-C: HDL-cholesterol. Values represent mean ± standard deviation.
실시예Example 6. 간 조직의 6. Liver tissue 오일레드Oil Red ( ( oiloil redred ) 염색 결과) Dyeing results
8주간 정상군, 대조군, 고욤잎 추출물 투여군 및 쿼세틴 투여군에 따른 간 조직의 지방축적의 변화를 알아보기 위해, 실험 종료 후 간 조직을 적출하여 급속 냉동 (-40℃)시켰고, 5 μm로 절박한 후 오일레드로 염색하여 관찰했다. 그 결과 도 2에 나타난 바와 같이 정상군에 비해 대조군의 간 조직에서 오일레드 양성 염색 정도가 현저하게 높았다. 반면에 고욤잎 추출물 투여군 및 쿼세틴 투여군은 대조군에 비해 오일레드 양성 염색 정도가 현저하게 낮은 것으로 나타났다.After 8 weeks, liver tissues were harvested and rapidly frozen (-40 ° C), followed by desensitization to 5 μM, to examine changes in fat accumulation of liver tissues according to the control group, control group, gomoma leaf extract group and quercetin group It was stained with oil red and observed. As a result, as shown in Fig. 2, the degree of oil-red positive staining was significantly higher in the liver tissue of the control group than in the normal group. On the other hand, the degree of oil - red - positive staining was significantly lower in the gouox leaf extract - treated group and the quercetin treated group than the control group.
Claims (5)
(b) 상기 제조한 고욤나무 잎 추출물의 치료적 유효량을 인간을 제외한 포유류에게 투여하여 비만을 개선하는 방법.(a) The collected gomam leaf was washed with water and steamed for 4 to 10 minutes. After removing moisture at room temperature, it was dried at 35 to 45 ° C for 10 to 14 hours in a drier, 220 g to 1800 to 2200 ml of water, boiling for 4 to 10 minutes, and filtering and lyophilizing the extract to prepare a gomam leaf extract; And
(b) A method for improving obesity by administering to a mammal other than a human a therapeutically effective amount of the gomoe leaf extract prepared above.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130061417A KR101464337B1 (en) | 2013-05-30 | 2013-05-30 | Composition for anti-obesity comprising extract of Diospyros lotus as effective component |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130061417A KR101464337B1 (en) | 2013-05-30 | 2013-05-30 | Composition for anti-obesity comprising extract of Diospyros lotus as effective component |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR101464337B1 true KR101464337B1 (en) | 2014-11-25 |
Family
ID=52291377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020130061417A KR101464337B1 (en) | 2013-05-30 | 2013-05-30 | Composition for anti-obesity comprising extract of Diospyros lotus as effective component |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101464337B1 (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101946818B1 (en) * | 2015-03-12 | 2019-02-13 | 주식회사 파미니티 | Composition for Improving Memory, Preventing, Improving or Treating Cognitive Disorder and Brain Diseases |
| KR101972588B1 (en) * | 2018-07-31 | 2019-04-26 | 정채홍 | Composition for pretreatment of lipolysis and fat removal treatment |
| KR20190102681A (en) * | 2018-02-27 | 2019-09-04 | 주식회사 아토큐앤에이 | Composition for preventing, ameliorating or treating metabolic diseases comprising mixture of Diospyros lotus leaf and grape fruit stem extract as effective component |
| KR20200044307A (en) * | 2018-10-19 | 2020-04-29 | 주식회사 아토큐앤에이 | Composition for anti-obesity and cellulite reduction comprising mixture of plant extract as effective component |
| CN111588028A (en) * | 2020-05-25 | 2020-08-28 | 北京硒哥硒生物科技有限公司 | Composition for losing weight and preparation method thereof |
| KR20210011036A (en) * | 2021-01-15 | 2021-01-29 | 주식회사 아토큐앤에이 | Composition for preventing, ameliorating or treating metabolic diseases comprising mixture of plant extract as effective component |
| KR102259214B1 (en) * | 2020-11-30 | 2021-05-31 | 한경훈 | Kimchi seasoning using functional substances and method for producing Kimchi using the same |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130018140A (en) * | 2011-08-12 | 2013-02-20 | 김길동 | Enzyme extraction method of the grain which uses the microbe and this in compliance with a method beverage which is manufactured |
-
2013
- 2013-05-30 KR KR1020130061417A patent/KR101464337B1/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130018140A (en) * | 2011-08-12 | 2013-02-20 | 김길동 | Enzyme extraction method of the grain which uses the microbe and this in compliance with a method beverage which is manufactured |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101946818B1 (en) * | 2015-03-12 | 2019-02-13 | 주식회사 파미니티 | Composition for Improving Memory, Preventing, Improving or Treating Cognitive Disorder and Brain Diseases |
| KR20190102681A (en) * | 2018-02-27 | 2019-09-04 | 주식회사 아토큐앤에이 | Composition for preventing, ameliorating or treating metabolic diseases comprising mixture of Diospyros lotus leaf and grape fruit stem extract as effective component |
| KR102025572B1 (en) * | 2018-02-27 | 2019-09-26 | 주식회사 아토큐앤에이 | Composition for preventing, ameliorating or treating metabolic diseases comprising mixture of Diospyros lotus leaf and grape fruit stem extract as effective component |
| KR101972588B1 (en) * | 2018-07-31 | 2019-04-26 | 정채홍 | Composition for pretreatment of lipolysis and fat removal treatment |
| KR20200044307A (en) * | 2018-10-19 | 2020-04-29 | 주식회사 아토큐앤에이 | Composition for anti-obesity and cellulite reduction comprising mixture of plant extract as effective component |
| KR102118866B1 (en) | 2018-10-19 | 2020-06-05 | 주식회사 아토큐앤에이 | Composition for anti-obesity and cellulite reduction comprising mixture of plant extract as effective component |
| CN111588028A (en) * | 2020-05-25 | 2020-08-28 | 北京硒哥硒生物科技有限公司 | Composition for losing weight and preparation method thereof |
| KR102259214B1 (en) * | 2020-11-30 | 2021-05-31 | 한경훈 | Kimchi seasoning using functional substances and method for producing Kimchi using the same |
| KR20210011036A (en) * | 2021-01-15 | 2021-01-29 | 주식회사 아토큐앤에이 | Composition for preventing, ameliorating or treating metabolic diseases comprising mixture of plant extract as effective component |
| KR102239066B1 (en) | 2021-01-15 | 2021-04-13 | 주식회사 아토큐앤에이 | Composition for preventing, ameliorating or treating metabolic diseases comprising mixture of plant extract as effective component |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101464337B1 (en) | Composition for anti-obesity comprising extract of Diospyros lotus as effective component | |
| US8084061B2 (en) | Body fat-reducing agent | |
| CN104688791B (en) | The composition for the saponin improved with bioavilability | |
| KR100860080B1 (en) | Pharmaceutical composition comprising the plant extract belonged to Veronica genus having anti-inflammatory, anti-allergic and-asthmatic activity | |
| US10617732B2 (en) | Composition including extract of Dolichos lablab Linne as active ingredient for preventing or ameliorating non-alcoholic fatty liver disease | |
| KR101691205B1 (en) | Composition comprising herbal extract for preventing or treating fatty liver disease | |
| JP2006045212A (en) | Oral composition containing specific quinic acid derivative | |
| JP2004091464A (en) | Obesity inhibitor | |
| CN108367039B (en) | Composition for treating or preventing liver disease comprising Citrullus spinosa extract as active ingredient | |
| EP1583547B1 (en) | Anti-obesity ingredients from medicinal plants and their composition | |
| KR20140137289A (en) | Composition comprising an extract of Alpinia officinarum Hance for preventing and treating hangover or liver disease | |
| KR101018403B1 (en) | composition comprising the extract of soybean leaves for the prevention?delay or treatment of gout | |
| KR101690369B1 (en) | Anti-obesity composition containing bitter melon mixture hot water extract and manufacturing method thereof | |
| WO2019083264A1 (en) | Composition for preventing, alleviating or treating liver diseases, containing fermented product of aged sprout ginseng extract as active ingredient | |
| KR20070097868A (en) | Composition comprising an allium cepa l. skin extract for preventing and treating diabetes mellitus | |
| KR102122408B1 (en) | Composition for preventing, ameliorating or treating andropause syndrome comprising roasted Glycyrrhiza uralensis extract as effective component | |
| KR20220067467A (en) | A composition comprising the ethanol extract of Corchorus olitorius for the prevention or treatment of alcoholic liver damage | |
| KR20160059152A (en) | Anti-obesity composition comprising Cirsium japonicum leaf extract as effective component | |
| KR100832520B1 (en) | A composition for the treatment or prevention of osteoporosis comprising an extract of capsosiphon fulvecense | |
| KR100888068B1 (en) | Compositions for suppressing obesity | |
| KR20140142516A (en) | A composition comprising the extract of Bupleurum falcatum (BF) and Physalis alkekengi var. francheti (PAF) as an active ingredient for preventing and treating inflammatory disease | |
| KR100473529B1 (en) | Composition comprising an extract of sungisan crude drug complex as an effective ingredient for preventing and treating diabetes | |
| KR101508561B1 (en) | Pharmaceutical composition containing extracts of mixed natural herb include avena sativa thereof for preventing and treating of Diabetic Disease | |
| KR102464897B1 (en) | Herbal Compositions for Prevention, Improvement or Treatment of Benign Prostatic Hyperplasia | |
| KR102236685B1 (en) | Composition for preventing or treating lipid metabolism diseases comprising extract of salvia miltiorrhiza or paeonia lactiflora |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20181218 Year of fee payment: 5 |